PCRX
Pacira BioSciences·NASDAQ
--
--(--)
--
--(--)
2.59 / 10
Underperform
Fundamental breakdown reveals a poor profile (2.6/10). Key limitations include low year-over-year revenue growth (3.08%) and negative profit-to-market-value gap (-1.62), both ranking in the weakest performance quartile. Supportive factors such as Days Sales Outstanding (58.27) and Interest Coverage Ratio (15.48) score higher but are insufficient to offset overall weakness. Historical back-tests show negative average monthly returns for these metrics, reinforcing the cautionary tone.
Analysis Checks(6/10)
Revenue-MV
Value0.10
Score2/3
Weight15.82%
1M Return7.73%
Value0.10
Score2/3
Weight15.82%
1M Return7.73%
Days sales outstanding
Value58.27
Score2/3
Weight1.76%
1M Return1.10%
Value58.27
Score2/3
Weight1.76%
1M Return1.10%
Net income-Revenue
Value-1.58
Score2/3
Weight16.14%
1M Return8.45%
Value-1.58
Score2/3
Weight16.14%
1M Return8.45%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.61%
1M Return-1.11%
Value15.48
Score2/3
Weight-1.61%
1M Return-1.11%
Asset-MV
Value-0.50
Score0/3
Weight11.52%
1M Return5.75%
Value-0.50
Score0/3
Weight11.52%
1M Return5.75%
Total operating revenue (YoY growth rate %)
Value3.08
Score1/3
Weight-1.18%
1M Return-0.79%
Value3.08
Score1/3
Weight-1.18%
1M Return-0.79%
Profit-MV
Value-1.62
Score2/3
Weight16.12%
1M Return8.45%
Value-1.62
Score2/3
Weight16.12%
1M Return8.45%
PB-ROE
Value-0.13
Score1/3
Weight19.63%
1M Return9.57%
Value-0.13
Score1/3
Weight19.63%
1M Return9.57%
Operating revenue (YoY growth rate %)
Value3.08
Score1/3
Weight-1.14%
1M Return-0.76%
Value3.08
Score1/3
Weight-1.14%
1M Return-0.76%
Cash-MV
Value0.47
Score3/3
Weight22.94%
1M Return9.67%
Value0.47
Score3/3
Weight22.94%
1M Return9.67%
Revenue-MV
Value0.10
Score2/3
Weight15.82%
1M Return7.73%
Value0.10
Score2/3
Weight15.82%
1M Return7.73%
Total operating revenue (YoY growth rate %)
Value3.08
Score1/3
Weight-1.18%
1M Return-0.79%
Value3.08
Score1/3
Weight-1.18%
1M Return-0.79%
Days sales outstanding
Value58.27
Score2/3
Weight1.76%
1M Return1.10%
Value58.27
Score2/3
Weight1.76%
1M Return1.10%
Profit-MV
Value-1.62
Score2/3
Weight16.12%
1M Return8.45%
Value-1.62
Score2/3
Weight16.12%
1M Return8.45%
Net income-Revenue
Value-1.58
Score2/3
Weight16.14%
1M Return8.45%
Value-1.58
Score2/3
Weight16.14%
1M Return8.45%
PB-ROE
Value-0.13
Score1/3
Weight19.63%
1M Return9.57%
Value-0.13
Score1/3
Weight19.63%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.61%
1M Return-1.11%
Value15.48
Score2/3
Weight-1.61%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value3.08
Score1/3
Weight-1.14%
1M Return-0.76%
Value3.08
Score1/3
Weight-1.14%
1M Return-0.76%
Asset-MV
Value-0.50
Score0/3
Weight11.52%
1M Return5.75%
Value-0.50
Score0/3
Weight11.52%
1M Return5.75%
Cash-MV
Value0.47
Score3/3
Weight22.94%
1M Return9.67%
Value0.47
Score3/3
Weight22.94%
1M Return9.67%
Is PCRX undervalued or overvalued?
- PCRX scores 2.59/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.72% ROE, 2.99% net margin, 40.26 P/E ratio, 1.19 P/B ratio, and 123.98% earnings growth, these metrics solidify its Underperform investment rating.
